Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 20/20 | 0.52 |
| ▸ | F3 | P13726 | 19/20 | 0.52 |
| ▸ | F10 | P00742 | 7/20 | 0.52 |
| ▸ | F2 | P00734 | 5/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.52 |
| ▸ | F11 | P03951 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5882260 | 0.92 | F7 (0.58) | F7F3F10F2PRSS1 | |
| SCHEMBL5882238 | 0.91 | F7 (0.42) | F7F3F10F2PRSS1 | |
| SCHEMBL5881839 | 0.91 | F7 (0.49) | F7F3F10F2PRSS1 | |
| SCHEMBL5881843 | 0.91 | F7 (0.49) | F7F3F10F2PRSS1 | |
| SCHEMBL7443963 | 0.91 | F7 (0.49) | F7F3F10F2PRSS1 | |
| SCHEMBL4333411 | 0.91 | F7 (0.49) | F7F3F10F2PRSS1 | |
| SCHEMBL5882845 | 0.90 | F7 (0.43) | F7F3F10F2PRSS1 | |
| SCHEMBL5882965 | 0.89 | F7 (0.56) | F7F3F10F2PRSS1 | |
| SCHEMBL5882977 | 0.89 | F7 (0.46) | F7F3F10F2PRSS1 | |
| SCHEMBL5882528 | 0.88 | F7 (0.48) | F7F3F10F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576098-B2 | Heterocyclic compounds as inhibitors of factor VIIa | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1828152-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA | BRISTOL MYERS SQUIBB CO (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1828152-A2 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA | Bristol-Myers Squibb Company (US) | 2007-09-05 | — | — | EP | disclosed |
| US-7250447-B2 | Acylsulfamide inhibitors of factor VIIa | GENENTECH, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250447-B2 | Acylsulfamide inhibitors of factor VIIa | GENENTECH, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20070037813-A1 | Serine Protease Inhibitors | GENENTECH, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037813-A1 | Serine Protease Inhibitors | GENENTECH, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037813-A1 | Serine Protease Inhibitors | GENENTECH, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037814-A1 | ACYLSULFAMIDE INHIBITORS OF FACTOR VIIa | GENENTECH, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037814-A1 | ACYLSULFAMIDE INHIBITORS OF FACTOR VIIa | GENENTECH, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20030083504-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2003-05-01 | — | — | US | disclosed |
| US-6476264-B2 | ANTICOAGULANT | HOFFMANN-LA ROCHE INC. | 2002-11-05 | — | — | US | disclosed |
| US-6472393-B1 | Serine protease inhibitors | GENENTECH, INC. | 2002-10-29 | — | — | US | disclosed |
| EP-1144373-A3 | SERINE PROTEASE INHIBITORS | Genentech, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1149069-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| EP-1144373-A2 | SERINE PROTEASE INHIBITORS | Genentech, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6242644-B1 | FOR TREATING THROMBOSIS, APOPLEXY, CARDIAC INFARCTION, INFLAMATION AND ARTHEROSCLEROSIS | HOFFMANN-LA ROCHE INC. | 2001-06-05 | — | — | US | disclosed |
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2001-05-24 | — | — | US | disclosed |
| WO-2000041531-A2 | SERINE PROTEASE INHIBITORS | GENENTECH, INC. (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000035858-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037813-A1 | Serine Protease Inhibitors | TFPI, SPINT2, SERPINE1 | F7 17/4885F3 43/4885F10 37/4885 |
| US-20070037814-A1 | ACYLSULFAMIDE INHIBITORS OF FACTOR VIIa | TFPI, HABP2, TFPI2 | F7 4/4885F3 41/4885F10 33/4885 |
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | F7 1019/4885F3 2017/4885F10 520/4885 |
| US-20030083504-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | F7 1019/4885F3 2017/4885F10 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.